Literature DB >> 24245956

B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL.

Gerardo Ferrer1, Rosa Bosch, Kate Hodgson, Rut Tejero, Gael Roué, Dolors Colomer, Emili Montserrat, Carol Moreno.   

Abstract

The two tumour necrosis factor family proteins BAFF (TNFSF13B) and APRIL (TNFSF13) and their receptors [BAFF-R (TNFRSF13C), TACI (TNFRSF13B), BCMA (TNFRSF17)] play a critical role in the survival of normal B cells. The sensitivity of normal B cells to BAFF and APRIL can be modulated by signals regulated by their receptors. This modulation, however, has not been extensively investigated in chronic lymphocytic leukaemia (CLL) cells. We evaluated the expression, regulation and signalling of BAFF and APRIL receptors in normal and in CLL cells upon stimulation through CD40+IL4R and BCR. We further analysed the prognostic value of BAFF and APRIL receptors expression in patients with CLL. BCMA expression was significantly higher on CLL cells than on normal B cells. BCR and CD40+IL4R stimulation promoted an increase in TACI and BCMA expression, cell viability and activation in normal B cells. A similar effect was observed in CLL cells after CD40+IL4R but not BCR stimulation. BCMA expression correlated with unmutated IGHV genes, poor-risk cytogenetics, and short progression-free survival. These findings further characterize the link between CD40+IL4R regulatory signals, BAFF, APRIL and their receptors and the survival of leukaemic cells and clinical features of CLL.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  B-cell maturation antigen; B-cell-activating factor; a proliferation-inducing ligand; chronic lymphocytic leukaemia; receptors modulation

Mesh:

Substances:

Year:  2013        PMID: 24245956     DOI: 10.1111/bjh.12645

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

Review 1.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

2.  Prognostic Significance of Serum BAFF, APRIL, TACI and BCMA Levels in Chronic Lymphocytic Leukemia.

Authors:  İlay Berke Menteşe; Zeynep Arzu Yegin; Sanem Gökçen; Zübeyde Nur Özkurt; Münci Yağcı
Journal:  Indian J Hematol Blood Transfus       Date:  2018-10-10       Impact factor: 0.900

3.  Is ibrutinib associated with disseminated cryptococcosis with CNS involvement?

Authors:  Muhammad Bilal Abid; Jeremiah Stromich; Nathan D Gundacker
Journal:  Cancer Biol Ther       Date:  2018-08-27       Impact factor: 4.742

Review 4.  Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia.

Authors:  Audrey Mohr; Yves Renaudineau; Cristina Bagacean; Jacques-Olivier Pers; Christophe Jamin; Anne Bordron
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

5.  BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Authors:  Hatice Gulcin Ozer; Dalia El-Gamal; Ben Powell; Gideon Bollag; John C Byrd; Rosa Lapalombella; Zachary A Hing; James S Blachly; Bonnie Harrington; Shaneice Mitchell; Nicole R Grieselhuber; Katie Williams; Tzung-Huei Lai; Lapo Alinari; Robert A Baiocchi; Lindsey Brinton; Elizabeth Baskin; Matthew Cannon; Larry Beaver; Virginia M Goettl; David M Lucas; Jennifer A Woyach; Deepa Sampath; Amy M Lehman; Lianbo Yu; Jiazhong Zhang; Yan Ma; Ying Zhang; Wayne Spevak; Songyuan Shi; Paul Severson; Rafe Shellooe; Heidi Carias; Garson Tsang; Ken Dong; Todd Ewing; Adhirai Marimuthu; Christina Tantoy; Jason Walters; Laura Sanftner; Hamid Rezaei; Marika Nespi; Bernice Matusow; Gaston Habets; Prabha Ibrahim; Chao Zhang; Ewy A Mathé
Journal:  Cancer Discov       Date:  2018-01-31       Impact factor: 39.397

6.  B-Cell Activating Factor Belonging to the Tumor Necrosis Factor Family and Interferon-γ-Inducible Protein-10 in Autoimmune Hepatitis.

Authors:  Hiroki Nishikawa; Hirayuki Enomoto; Yoshinori Iwata; Kyohei Kishino; Yoshihiro Shimono; Kunihiro Hasegawa; Chikage Nakano; Ryo Takata; Takashi Nishimura; Kazunori Yoh; Akio Ishii; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  B-cell maturation antigen expression across hematologic cancers: a systematic literature review.

Authors:  Ahmet Dogan; David Siegel; Nguyet Tran; Alan Fu; Jessica Fowler; Rajesh Belani; Ola Landgren
Journal:  Blood Cancer J       Date:  2020-06-30       Impact factor: 11.037

Review 8.  Critical molecular pathways in CLL therapy.

Authors:  Gerardo Ferrer; Emili Montserrat
Journal:  Mol Med       Date:  2018-03-15       Impact factor: 6.354

9.  Transcriptomic Analysis of Spleen Revealed Mechanism of Dexamethasone-Induced Immune Suppression in Chicks.

Authors:  Yujie Guo; Aru Su; Huihui Tian; Minxi Zhai; Wenting Li; Yadong Tian; Kui Li; Guirong Sun; Ruirui Jiang; Ruili Han; Fengbin Yan; Xiangtao Kang
Journal:  Genes (Basel)       Date:  2020-05-06       Impact factor: 4.096

10.  CXXC5 Attenuates Pulmonary Fibrosis in a Bleomycin-Induced Mouse Model and MLFs by Suppression of the CD40/CD40L Pathway.

Authors:  Wei Cheng; Fangfang Wang; Airan Feng; Xiaodan Li; Wencheng Yu
Journal:  Biomed Res Int       Date:  2020-04-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.